These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37395026)

  • 1. CRISPR/Cas9-Mediated Gene Correction in Osteopetrosis Patient-Derived iPSCs.
    Li D; Ou M; Zhang W; Luo Q; Cai W; Mo C; Liang W; Dai G; Yin L; Zhu P; Tang D; Dai Y
    Front Biosci (Landmark Ed); 2023 Jun; 28(6):131. PubMed ID: 37395026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genotyping, generation and proteomic profiling of the first human autosomal dominant osteopetrosis type II-specific induced pluripotent stem cells.
    Ou M; Li C; Tang D; Xue W; Xu Y; Zhu P; Li B; Xie J; Chen J; Sui W; Yin L; Dai Y
    Stem Cell Res Ther; 2019 Aug; 10(1):251. PubMed ID: 31412925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteopetrotic induced pluripotent stem cells derived from patients with different disease-associated mutations by non-integrating reprogramming methods.
    Okur FV; Cevher İ; Özdemir C; Kocaefe Ç; Çetinkaya DU
    Stem Cell Res Ther; 2019 Jul; 10(1):211. PubMed ID: 31315669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Footprint-free gene mutation correction in induced pluripotent stem cell (iPSC) derived from recessive dystrophic epidermolysis bullosa (RDEB) using the CRISPR/Cas9 and piggyBac transposon system.
    Itoh M; Kawagoe S; Tamai K; Nakagawa H; Asahina A; Okano HJ
    J Dermatol Sci; 2020 Jun; 98(3):163-172. PubMed ID: 32376152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chloride channel 7 (ClCN7) gene mutations and autosomal dominant osteopetrosis, type II.
    Waguespack SG; Koller DL; White KE; Fishburn T; Carn G; Buckwalter KA; Johnson M; Kocisko M; Evans WE; Foroud T; Econs MJ
    J Bone Miner Res; 2003 Aug; 18(8):1513-8. PubMed ID: 12929941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of a human induced pluripotent stem cell line (BIHi002-A) from a patient with CLCN7-related infantile malignant autosomal recessive osteopetrosis.
    Hennig AF; Rössler U; Boiti F; von der Hagen M; Gossen M; Kornak U; Stachelscheid H
    Stem Cell Res; 2019 Mar; 35():101367. PubMed ID: 30763735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determining the Pathogenicity of a Genomic Variant of Uncertain Significance Using CRISPR/Cas9 and Human-Induced Pluripotent Stem Cells.
    Ma N; Zhang JZ; Itzhaki I; Zhang SL; Chen H; Haddad F; Kitani T; Wilson KD; Tian L; Shrestha R; Wu H; Lam CK; Sayed N; Wu JC
    Circulation; 2018 Dec; 138(23):2666-2681. PubMed ID: 29914921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful correction of factor V deficiency of patient-derived iPSCs by CRISPR/Cas9-mediated gene editing.
    Nakamura T; Morishige S; Ozawa H; Kuboyama K; Yamasaki Y; Oya S; Yamaguchi M; Aoyama K; Seki R; Mouri F; Osaki K; Okamura T; Mizuno S; Nagafuji K
    Haemophilia; 2020 Sep; 26(5):826-833. PubMed ID: 32700411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiomics landscape of the autosomal dominant osteopetrosis type II disease-specific induced pluripotent stem cells.
    Li C; Shangguan Y; Zhu P; Dai W; Tang D; Ou M; Dai Y
    Hereditas; 2021 Oct; 158(1):40. PubMed ID: 34702373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correction of Hirschsprung-Associated Mutations in Human Induced Pluripotent Stem Cells Via Clustered Regularly Interspaced Short Palindromic Repeats/Cas9, Restores Neural Crest Cell Function.
    Lai FP; Lau ST; Wong JK; Gui H; Wang RX; Zhou T; Lai WH; Tse HF; Tam PK; Garcia-Barcelo MM; Ngan ES
    Gastroenterology; 2017 Jul; 153(1):139-153.e8. PubMed ID: 28342760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved hematopoietic differentiation efficiency of gene-corrected beta-thalassemia induced pluripotent stem cells by CRISPR/Cas9 system.
    Song B; Fan Y; He W; Zhu D; Niu X; Wang D; Ou Z; Luo M; Sun X
    Stem Cells Dev; 2015 May; 24(9):1053-65. PubMed ID: 25517294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR/Cas9 mediated gene correction ameliorates abnormal phenotypes in spinocerebellar ataxia type 3 patient-derived induced pluripotent stem cells.
    He L; Wang S; Peng L; Zhao H; Li S; Han X; Habimana JD; Chen Z; Wang C; Peng Y; Peng H; Xie Y; Lei L; Deng Q; Wan L; Wan N; Yuan H; Gong Y; Zou G; Li Z; Tang B; Jiang H
    Transl Psychiatry; 2021 Sep; 11(1):479. PubMed ID: 34535635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naïve Induced Pluripotent Stem Cells Generated From β-Thalassemia Fibroblasts Allow Efficient Gene Correction With CRISPR/Cas9.
    Yang Y; Zhang X; Yi L; Hou Z; Chen J; Kou X; Zhao Y; Wang H; Sun XF; Jiang C; Wang Y; Gao S
    Stem Cells Transl Med; 2016 Jan; 5(1):8-19. PubMed ID: 26676643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of a gene corrected human isogenic IBMS-iPSC-014-C from polycystic-kidney-disease induced pluripotent stem cell line using CRISPR/Cas9.
    Liu CL; Huang CY; Chen HC; Lu HE; Hsieh PCH; Lee JJ
    Stem Cell Res; 2020 May; 45():101784. PubMed ID: 32361310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR/Cas9-mediated gene correction in hemophilia B patient-derived iPSCs.
    Morishige S; Mizuno S; Ozawa H; Nakamura T; Mazahery A; Nomura K; Seki R; Mouri F; Osaki K; Yamamura K; Okamura T; Nagafuji K
    Int J Hematol; 2020 Feb; 111(2):225-233. PubMed ID: 31664646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic Correction of Induced Pluripotent Stem Cells From a Deaf Patient With MYO7A Mutation Results in Morphologic and Functional Recovery of the Derived Hair Cell-Like Cells.
    Tang ZH; Chen JR; Zheng J; Shi HS; Ding J; Qian XD; Zhang C; Chen JL; Wang CC; Li L; Chen JZ; Yin SK; Huang TS; Chen P; Guan MX; Wang JF
    Stem Cells Transl Med; 2016 May; 5(5):561-71. PubMed ID: 27013738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease status in autosomal dominant osteopetrosis type 2 is determined by osteoclastic properties.
    Chu K; Snyder R; Econs MJ
    J Bone Miner Res; 2006 Jul; 21(7):1089-97. PubMed ID: 16813529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Both TALENs and CRISPR/Cas9 directly target the HBB IVS2-654 (C > T) mutation in β-thalassemia-derived iPSCs.
    Xu P; Tong Y; Liu XZ; Wang TT; Cheng L; Wang BY; Lv X; Huang Y; Liu DP
    Sci Rep; 2015 Jul; 5():12065. PubMed ID: 26156589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcriptomic and bioinformatic analysis of Clcn7-dependent Autosomal Dominant Osteopetrosis type 2. Preclinical and clinical implications.
    Norwood I; Szondi D; Ciocca M; Coudert A; Cohen-Solal M; Rucci N; Teti A; Maurizi A
    Bone; 2021 Mar; 144():115828. PubMed ID: 33359007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using CRISPR-Cas9 to Generate Gene-Corrected Autologous iPSCs for the Treatment of Inherited Retinal Degeneration.
    Burnight ER; Gupta M; Wiley LA; Anfinson KR; Tran A; Triboulet R; Hoffmann JM; Klaahsen DL; Andorf JL; Jiao C; Sohn EH; Adur MK; Ross JW; Mullins RF; Daley GQ; Schlaeger TM; Stone EM; Tucker BA
    Mol Ther; 2017 Sep; 25(9):1999-2013. PubMed ID: 28619647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.